REG - Diaceutics PLC - Issue of Share Options/PDMR Shareholdings

DiaceuticsAnnouncement

25/10/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241025:nRSY5657Ja&default-theme=true

RNS Number : 5657J  Diaceutics PLC  25 October 2024

 

Diaceutics PLC - Issue of Share Options/PDMR Shareholdings

("Diaceutics" or the "Company")

Belfast and London, 25 October 2024 - Diaceutics (https://www.diaceutics.com/)
PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and
biotech industry, announces the issue of 773,777 share options over ordinary
shares of £0.002 each in the Company ("Share Options") to certain directors
and a member of the Company's senior management team, pursuant to the
Company's Employee Share Option Plan ("ESOP").

The Share Options were granted as follows:

 

Ryan Keeling (CEO) & Nick Roberts (CFO)

557,953 Share Options were granted to Ryan Keeling and 139,488 Share Options
to Nick Roberts on 24 October 2024. These Share Options are granted over the
balance of ordinary shares held in the Company's Employee Benefit Trust
("EBT") which have not been utilised to satisfy other employee share options
at the time of exercise and are therefore non-dilutive to shareholders. The
shares held by the EBT were originally gifted by Peter Keeling (Non-Executive
Chairman and a co-founder) to the EBT pre-IPO with intention that the shares
be used to incentivise directors and employees of the Company.

 

The Share Options will vest in full upon the satisfaction of certain
shareholder value performance criteria over the performance period, being five
years from the date of grant. The performance criteria are based upon growth
in Total Shareholder Return ("TSR") during the performance period, the
successful sole or joint listing of the Company on an alternative public stock
exchange and other customary corporate events. The exercise price of the Share
Options is £0.002 per share which equates to the nominal value of the
ordinary shares.

 

The Share Options are granted over the balance of ordinary shares outstanding
in the EBT at the point of exercise and may change depending on the number of
outstanding ordinary shares in the EBT at that time.

 

Subsequent to the grant of the above Share Options, Ryan Keeling has 1,139,900
shares under option which represents 1.35% of the existing issued share
capital of the Company and Nick Roberts has 467,110 shares under option which
represents 0.55% of the existing issued share capital of the Company.

 

Sandra Blake, Chief People Officer (CPO)

76,336 Share Options were granted to Sandra Blake, a Person Discharging
Managerial Responsibilities ('PDMR'), on 22 October 2024. The Share Options
vest on a sliding scale up to 100%, during the performance period from the
date of grant to 27 July 2027, subject to the satisfaction of certain
performance criteria. The performance criteria are based upon the growth
during the performance period in TSR, the revenue Compound Annual Growth Rate
("CAGR") and recurring revenue. The exercise price of the Share Options is
£0.002 per share which equates to the nominal value of the ordinary shares.
Subsequent to the grant, Sandra Blake has 76,336 shares under option which
represents 0.09% of the existing issued share capital of the Company.

 

These awards are made in accordance with the Company's long term incentive
plan as detailed in the Company's Annual Report.

 

Following this grant, the total number of share options outstanding in the
Company is 5,168,180 representing approximately 6.10% of its current issued
share capital of 84,726,935.

 

 

 Enquiries:

Diaceutics PLC
 Ryan Keeling, Chief Executive Officer           Tel: +44 (0)28 9040 6500

 Nick Roberts, Chief Financial Officer           investorrelations@diaceutics.com (mailto:investorrelations@diaceutics.com)

 Canaccord Genuity Limited (Nomad & Broker)      Tel: +44 (0)20 7523 8000
 Simon Bridges, Andrew Potts, Harry Rees

 Alma Strategic Communications                   Tel: +44(0)20 3405 0205
 Caroline Forde, Kinvara Verdon                  diaceutics@almastrategic.com

 

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact their
disease outcome. We provide the world's leading pharma and biotech companies
with an end-to-end commercialisation solution for precision medicines through
data analytics, scientific and advisory services enabled by our platform DXRX
- The Diagnostics Network ®.

 

The following additional information is disclosed in accordance with article
19(3) of the Market Abuse Regulation.

 

 Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
 596/2014
 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a.  Name                                                         Ryan Keeling
 2   Reason for notification
 a.  Position/Status                                              Chief Executive Officer of Diaceutics plc
 b.  Initial notification/                                        Initial

     Amendment
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a.  Name                                                         Diaceutics plc
 b.  LEI                                                          213800VEWQBB39ZB8J81
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a.  Description of the financial instrument, type of instrument  Ordinary shares of 0.2 p each

Identification Code

                                                                  ISIN:  GB00BJQTGV64
 b.  Nature of the transaction                                    Grant of share options
 c.  Price(s) and volume(s)
                                                                               Price(s)     Volume(s)
     Exercise price of 0.2p per share                                          557,953

 e.  Date of the transaction                                      24 October 2024
 f.  Place of the transaction                                     Outside a trading venue

 

 

 Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
 596/2014
 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a.  Name                                                         Nick Roberts
 2   Reason for notification
 a.  Position/Status                                              Chief Financial Officer of Diaceutics plc
 b.  Initial notification/                                        Initial

     Amendment
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a.  Name                                                         Diaceutics plc
 b.  LEI                                                          213800VEWQBB39ZB8J81
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a.  Description of the financial instrument, type of instrument  Ordinary shares of 0.2 p each

Identification Code

                                                                  ISIN:  GB00BJQTGV64
 b.  Nature of the transaction                                    Grant of share options
 c.  Price(s) and volume(s)
                                                                               Price(s)     Volume(s)
     Exercise price of 0.2p per share                                          139,488

 e.  Date of the transaction                                      24 October 2024
 f.  Place of the transaction                                     Outside a trading venue

 

 Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
 596/2014
 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a.  Name                                                         Sandra Blake
 2   Reason for notification
 a.  Position/Status                                              Chief People Officer of Diaceutics plc
 b.  Initial notification/                                        Initial

     Amendment
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a.  Name                                                         Diaceutics plc
 b.  LEI                                                          213800VEWQBB39ZB8J81
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a.  Description of the financial instrument, type of instrument  Ordinary shares of 0.2 p each

Identification Code

                                                                  ISIN:  GB00BJQTGV64
 b.  Nature of the transaction                                    Grant of share options
 c.  Price(s) and volume(s)
                                                                               Price(s)     Volume(s)
     Exercise price of 0.2p per share                                          76,336

 e.  Date of the transaction                                      22 October 2024
 f.  Place of the transaction                                     Outside a trading venue

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFZLLLZBLBFBL